{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:08:26Z","timestamp":1791274106173,"version":"4.1.0"},"reference-count":14,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Interstitial lung disease (ILD) is characterized by pulmonary inflammation and fibrosis associated with persistent and refractory cough that significantly hinders quality of life. Conventional treatments for ILD-associated cough have shown limited efficacy, necessitating alternative therapeutic approaches. Gefapixant, a P2X3 receptor antagonist, can potentially alleviate chronic cough by inhibiting the ATP-mediated activation of sensory C-fibers, but its efficacy in ILD-associated cough remains unclear. This study observed the effects of gefapixant on ILD-associated refractory chronic cough. Methods: This prospective study enrolled patients with ILD-associated refractory chronic cough who received gefapixant at Sapporo Medical University Hospital between July 2022 and November 2023. Cough frequency, Leicester Cough Questionnaire (LCQ) score, cough severity visual analog scale (Cough VAS), and taste VAS were evaluated at baseline and at 2, 4, and 8 weeks after gefapixant administration. Results: Six patients completed the study. Their ILD subtypes included idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), and connective tissue disease-associated ILDs (CTD-ILDs). After 8 weeks, the cough frequency decreased from 88.5 to 44.3 episodes per 30 min, LCQ scores increased from 8.3 to 13.6, and cough VAS scores decreased from 75.8 to 40.2. However, statistical significance was not reached due to high interindividual variability, with gefapixant being effective in some and ineffective in others. The most common adverse event was taste disorder, leading to discontinuation in one patient, but symptoms tended to lessen over the course of treatment. Conclusions: Gefapixant appears to be effective in reducing refractory cough related to ILD, although these results were not statistically significant because its effectivity widely varied across individuals. Further investigation is needed to identify patient subgroups with the greatest potential for treatment responsiveness.<\/jats:p>","DOI":"10.3390\/medicina61050892","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:06:52Z","timestamp":1747217212000},"page":"892","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8478-5646","authenticated-orcid":false,"given":"Tomoyuki","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, School of Medicine, Sapporo Medical University, Sapporo 060-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-884X","authenticated-orcid":false,"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, School of Medicine, Sapporo Medical University, Sapporo 060-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-9883","authenticated-orcid":false,"given":"Takafumi","family":"Yorozuya","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, School of Medicine, Sapporo Medical University, Sapporo 060-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-9344","authenticated-orcid":false,"given":"Hirotaka","family":"Nishikiori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, School of Medicine, Sapporo Medical University, Sapporo 060-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2743-3266","authenticated-orcid":false,"given":"Koji","family":"Kuronuma","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, School of Medicine, Sapporo Medical University, Sapporo 060-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, School of Medicine, Sapporo Medical University, Sapporo 060-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pupt.2015.10.009","article-title":"Cough in interstitial lung disease","volume":"35","author":"Garner","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.chest.2021.05.071","article-title":"Managing Cough in Idiopathic Pulmonary Fibrosis","volume":"160","author":"Wakwaya","year":"2021","journal-title":"Chest"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1745-9974-7-2","article-title":"Mechanical induction of cough in Idiopathic Pulmonary Fibrosis","volume":"7","author":"Jones","year":"2011","journal-title":"Cough"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1164\/rccm.201003-0359OC","article-title":"Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis","volume":"182","author":"Riteau","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1900439","DOI":"10.1183\/13993003.00439-2019","article-title":"The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: A randomised placebo-controlled study","volume":"54","author":"Morice","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"L858","DOI":"10.1152\/ajplung.90360.2008","article-title":"P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus","volume":"295","author":"Kwong","year":"2008","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s41030-021-00162-9","article-title":"Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial","volume":"7","author":"Martinez","year":"2021","journal-title":"Pulm. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1901136","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.resinv.2021.01.007","article-title":"The Japanese respiratory society guidelines for the management of cough and sputum (digest edition)","volume":"59","author":"Mukae","year":"2021","journal-title":"Respir. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS\/JRS\/ALAT Clinical Practice Guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","article-title":"Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): Results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials","volume":"399","author":"McGarvey","year":"2022","journal-title":"Lancet"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/892\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:28Z","timestamp":1760031148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["medicina61050892"],"URL":"https:\/\/doi.org\/10.3390\/medicina61050892","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}